- Heron Therapeutics Inc HRTX has submitted a supplemental marketing application for Zynrelef (bupivacaine and meloxicam) extended-release solution to support the proposed indication for expanded use of Zynrelef in soft tissue and orthopedic surgical procedures.
- Zynrelef is currently indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot & ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
- Related: Analysts Cut Price Targets As Heron Therapeutics' Zynrelef Disappoints In Q3.
- The application also supports a newly passed congressional bill anticipated to provide separate reimbursement outside the package surgical payment for Zynrelef for almost three years between 1 January 2025 - 31 December 2027.
- In two Phase 3 trials, Zynrelef demonstrated the ability to significantly increase the proportion of patients taking no opioids after surgery.
- The company says separate payments from CMS are anticipated to accelerate the uptake of Zynrelef in large hospital systems significantly.
- Price Action: HRTX shares are up 6.00% at $2.39 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
